# Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies

> **NCT04162756** · — · APPROVED_FOR_MARKETING · sponsor: **Kite, A Gilead Company**

## Conditions studied

- Relapse/Refractory Mantle Cell Lymphoma

## Interventions

- **BIOLOGICAL:** Brexucabtagene Autoleucel (KTE-X19)
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04162756
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04162756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04162756, "Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04162756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*